Homepage>Company>Media>Pharma News>2022>CTI BioPharma Granted FDA Accelerated Approval of Vonjo (pacritinib) for the Treatment of Myelofibrosis and Thrombocytopenia
CTI BioPharma Granted FDA Accelerated Approval of Vonjo (pacritinib) for the Treatment of Myelofibrosis and Thrombocytopenia